Wealth Enhancement Advisory Services’s ADMA Biologics ADMA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$438K	Buy	63,254 +32,507	+106%	+$296K	﹤0.01%	2816
2026 Q1	$95.7K	Buy	30,747 +24,684	+407%	+$390K	﹤0.01%	3325
2025 Q4	$117K	Buy	6,063 +634	+12%	+$10.7K	﹤0.01%	3402
2025 Q3	$76K	Buy	+5,429	New	+$93.1K	﹤0.01%	3373

Other funds holding ADMA

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

Wealth Enhancement Advisory Services's ADMA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its ADMA Biologics (ADMA) stake by 106% in Q2 2026, buying an estimated $296K and bringing the position to 63,254 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #2816.

Wealth Enhancement Advisory Services first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. 41 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Wealth Enhancement Advisory Services held 63,254 shares of ADMA Biologics worth $438K as of Q2 2026.
Wealth Enhancement Advisory Services bought 32,507 ADMA Biologics shares in Q2 2026, an estimated $296K.
ADMA Biologics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2816 holding.
Wealth Enhancement Advisory Services first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
41 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.